Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Funga...
SCYNEXIS, Inc. (SCYX)
Last scynexis, inc. earnings: 11/12 08:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.scynexis.com/investor-relations
Company Research
Source: GlobeNewswire
Five-year grant of $7 million annually to the academic researchers is aimed at accelerating the development of new therapeutics to combat resistant fungal infections, including the Company’s next generation of triterpenoid antifungals (fungerps).Next-generation fungerps, in preclinical stages of development, are targeted to have enhanced pharmacological properties to treat fungal infections where current therapies are limited or not effective, while maintaining broad spectrum of activity against resistant fungal pathogens. JERSEY CITY, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that a novel series of antifungal compounds utilizing SCYNEXIS’ proprietary triterpenoid antifungal platform are among the five projects funded by the federal grant awarded to the new accelerator consortium led by researchers from Hacke
Show less
Read more
Impact Snapshot
Event Time:
SCYX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SCYX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SCYX alerts
High impacting SCYNEXIS, Inc. news events
Weekly update
A roundup of the hottest topics
SCYX
News
- SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSKGlobeNewswire
- SCYNEXIS (NASDAQ:SCYX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- SCYNEXIS (NASDAQ:SCYX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
- SCYNEXIS (NASDAQ:SCYX) had its price target lowered by analysts at Guggenheim from $4.00 to $3.00. They now have a "buy" rating on the stock.MarketBeat
SCYX
Earnings
- 11/5/25 - Beat
SCYX
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form SCHEDULE
- 11/5/25 - Form 10-Q
- SCYX's page on the SEC website